Vaccination of cattle against B. bovis infection with live attenuated parasites and non-viable immunogens

Fish, L.; Leibovich, Benjamin; Krigel, Y.; McElwain, Terry F.; Shkap, Varda

doi:10.1016/j.vaccine.2008.09.070

Cited by 34 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apparently priming steers with rMSA‐1, rMSA‐2c and r12D3 and adjuvant elicit responses that may be weak, and therefore clinical symptoms were observed in vaccinated as well as in non‐vaccinated animals. Also, recombinant proteins 12D3 and 11C5 were reported to induce partial protective immunity upon challenge with virulent parasites (Wright et al., 1992; Hope et al., 2005; Fish et al., 2008). Because of the lack of safe and effective anti‐parasitic drugs for babesiosis in cattle, the increasing resistance to use of chemical products and the problems associated with tick control, development of efficacious vaccines are needed that will induce strong immunological memory responses and result in protection against clinical disease (Crampton and Vanniasinkam, 2007).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunization of Bos taurus Steers with Babesia bovis Recombinant Antigens MSA-1, MSA-2c and 12D3

Alvarez

López

Rojas

et al. 2010

Transboundary and Emerging Diseases

View full text Add to dashboard Cite

The purpose of this research was to evaluate the recombinant proteins MSA-1, MSA-2c and 12D3 as a combined immunogen for cattle. Fifteen steers were randomly assigned into three groups of five animals each (I, II and III). On day 0, cattle in group I were injected with 50 microg each of rMSA-1, rMSA-2c and r12D3 with the adjuvant Montanide 75; cattle in Group II received adjuvant-PBS, and Group III were untreated controls. On day 14, cattle in Group I received a second injection of the three recombinant proteins in adjuvant and cattle in Group II again received adjuvant alone. On day 28, all groups of cattle were challenged with a field strain of Babesia bovis. After challenge, the experimental cattle were clinically and serologically monitored. Three of the five steers immunized with the combined recombinant B. bovis proteins seroconverted on day 14 post-immunization (P.I.) and the maximum titre was 1 : 1600. All five immunized steers presented strong seropositivity to B. bovis antigens at day 21 P.I. The prepatent periods of vaccinated cattle were delayed until day 10 post-challenge exposure versus 8 and 7 days in Groups II and III, respectively. Cattle in all groups had fever above 41 degrees C; the reduction in packed cell volume was not significantly different (P > 0.05) in vaccinated group I compared with Groups II and III (29% versus 26% and 31%, respectively). Treatment was required for one steer in the control group. During the period of the study, the weight of cattle in Groups I and II increased an average of 9 and 7 kg, whereas the weight of the control cattle was reduced on average 4 kg. Immunization with rMSA-1-rMSA-2c-r12D3 proteins was not sufficient to prevent clinical symptoms against challenge, but the immunologic response was sufficient to protect steers against a mild virulent strain of B. bovis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Live vaccines are available but immunization with recombinant protein antigens has been suggested as a new approach for control of bovine babesiosis. (Wright et al, 1992; Norimine et al., 2003; Fish et al., 2008; Willadsen, 2008).…”

Section: Introductionmentioning

confidence: 99%

Immunization of Bos taurus Steers with Babesia bovis Recombinant Antigens MSA-1, MSA-2c and 12D3

Alvarez

López

Rojas

et al. 2010

Transboundary and Emerging Diseases

View full text Add to dashboard Cite

show abstract

“…Despite many shortcomings the attenuated vaccines at the present time are the best strategy for bovine babesiosis prevention ( 31 ). B. bovis attenuated vaccines produced both in vivo or in vitro , are infective and can induce similar solid protection against virulent challenge ( 106 , 107 , 120 , 121 ). Timms and Stewart ( 122 ) combined the stationary culture and suspension culture systems to scale B. bovis proliferation as a live vaccine.…”

Section: Experiences On Live Attenuated Vaccines From Other Countriesmentioning

confidence: 99%

An Overview of Current Knowledge on in vitro Babesia Cultivation for Production of Live Attenuated Vaccines for Bovine Babesiosis in Mexico

2020

View full text Add to dashboard Cite

The instrumentation of the in vitro culture system has allowed researchers to learn more about the metabolic and growth behavior of Babesia spp. The various applications for in vitro cultivation of Babesia include obtaining attenuated strains for vaccination or pre-munition, the selection of pure lines with different degrees of virulence, studies on biological cloning, ultrastructure, antigen production for diagnostics, drug sensitivity assessments, and different aspects of parasite biology. Although there are different types of vaccines that have been tested against bovine babesiosis, so far, the only procedure that has offered favorable results in terms of protection and safety has been the use of live attenuated vaccines. In countries, such as Australia, Argentina, Brazil, Uruguay and Israel, this type of vaccine has been produced and used. The alternative to live vaccines other than splenectomized calf-derived biological material, has been the in vitro cultivation of Babesia bovis and B. bigemina . The development of in vitro culture of Babesia spp. strains in a defined medium has been the basis for the initiation of a source of parasites and exoantigens for a variety of studies on the biochemistry and immunology of babesiosis. The use of live immunogens from attenuated strains derived from in vitro culture is highlighted, which has been proposed as an alternative to control bovine babesiosis. In several studies performed in Mexico, this type of immunogen applied to susceptible cattle has shown the induction of protection against the experimental heterologous strain challenge with both, Babesia -infected blood and animal exposure to confrontations on tick vector-infested farms. The combination of transfection technologies and the in vitro culture system as integrated methodologies would eventually give rise to the generation of genetically modified live vaccines. However, a greater challenge faced now by researchers is the large-scale cultivation of Babesia parasites for mass production and vaccine distribution.

show abstract

“…Live vaccines have many drawbacks such as the requirement of a cold chain, a short shelf life, and the potential for the transmission of concurrent pathogens and for reversion to virulence (Shkap and Pipano, 2000;Fish et al, 2008). Because of the shortcomings, there is still the need for additional research on the development of alternative safer and better defined live or subunit vaccines.…”

Section: Searching For Subunit Vaccine Targetsmentioning

confidence: 99%

Emerging perspectives in the research of bovine babesiosis and anaplasmosis

Suárez

Noh

2011

Veterinary Parasitology

184

135

View full text Add to dashboard Cite

Vaccination of cattle against B. bovis infection with live attenuated parasites and non-viable immunogens

Cited by 34 publications

References 34 publications

Immunization of Bos taurus Steers with Babesia bovis Recombinant Antigens MSA-1, MSA-2c and 12D3

Immunization of Bos taurus Steers with Babesia bovis Recombinant Antigens MSA-1, MSA-2c and 12D3

An Overview of Current Knowledge on in vitro Babesia Cultivation for Production of Live Attenuated Vaccines for Bovine Babesiosis in Mexico

Emerging perspectives in the research of bovine babesiosis and anaplasmosis

Contact Info

Product

Resources

About